Inhibitors of Apoptosis Proteins (IAPs) are natural regulators of cell death, often overexpressed in cancer cells. IAP inhibitors, such as Birinapant and LCL161, suppress these proteins, thereby reactivating the apoptotic process in cancer cells. This makes them promising candidates for targeted cancer therapies, forcing malignant cells to undergo apoptosis and halt their uncontrolled growth. By blocking the inhibitors of apoptosis, IAP inhibitors open new avenues for cancer treatment.
